These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38235716)

  • 1. Antibody-Mediated Serum Resistance Protects Pseudomonas aeruginosa During Bloodstream Infections.
    Hickson SM; Hoehensteiger JK; Mayer-Coverdale J; Torres VVL; Feng W; Monteith JN; Henderson IR; McCarthy KL; Wells TJ
    J Infect Dis; 2024 Aug; 230(2):e221-e229. PubMed ID: 38235716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cloaking antibodies are prevalent in
    Pham A; Tan KKY; Ledger EL; Smith DJ; Reid DW; Burr L; Chambers DC; Wells TJ
    Front Cell Infect Microbiol; 2024; 14():1426773. PubMed ID: 39193503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pseudomonas aeruginosa Bacteremic Patients Exhibit Nonprotective Antibody Titers Against Therapeutic Antibody Targets PcrV and Psl Exopolysaccharide.
    Thaden JT; Keller AE; Shire NJ; Camara MM; Otterson L; Huband M; Guenther CM; Zhao W; Warrener P; Stover CK; Fowler VG; DiGiandomenico A
    J Infect Dis; 2016 Feb; 213(4):640-8. PubMed ID: 26333940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P. aeruginosa blood stream infection isolates: A "full house" of virulence genes in isolates associated with rapid patient death and patient survival.
    McCarthy KL; Wailan AM; Jennison AV; Kidd TJ; Paterson DL
    Microb Pathog; 2018 Jun; 119():81-85. PubMed ID: 29621565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inferior outcomes in lung transplant recipients with serum Pseudomonas aeruginosa specific cloaking antibodies.
    Divithotawela C; Pham A; Bell PT; Ledger EL; Tan M; Yerkovich S; Grant M; Hopkins PM; Wells TJ; Chambers DC
    J Heart Lung Transplant; 2021 Sep; 40(9):951-959. PubMed ID: 34226118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiological analysis of serum anti-Pseudomonas aeruginosa PcrV titers in adults.
    Yasumoto H; Katoh H; Kinoshita M; Shimizu M; Hamaoka S; Akiyama K; Naito Y; Sawa T
    Microbiol Immunol; 2016 Feb; 60(2):114-20. PubMed ID: 26696420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-LPS IgA and IgG Can Inhibit Serum Killing of Pseudomonas aeruginosa in Patients with Cystic Fibrosis.
    Pham A; Ledger EL; Coggon CF; Henderson IR; Reid DW; Bell SC; Smith DJ; Wells TJ
    Infect Immun; 2021 Nov; 89(12):e0041221. PubMed ID: 34460286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Novel Method of Serum Resistance by Escherichia coli That Causes Urosepsis.
    Coggon CF; Jiang A; Goh KGK; Henderson IR; Schembri MA; Wells TJ
    mBio; 2018 Jun; 9(3):. PubMed ID: 29946047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results from a 13-Year Prospective Cohort Study Show Increased Mortality Associated with Bloodstream Infections Caused by Pseudomonas aeruginosa Compared to Other Bacteria.
    Thaden JT; Park LP; Maskarinec SA; Ruffin F; Fowler VG; van Duin D
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Predictive Model of Multidrug Resistance in Neutropenic Cancer Patients with Bloodstream Infection Due to Pseudomonas aeruginosa.
    Gudiol C; Albasanz-Puig A; Laporte-Amargós J; Pallarès N; Mussetti A; Ruiz-Camps I; Puerta-Alcalde P; Abdala E; Oltolini C; Akova M; Montejo M; Mikulska M; Martín-Dávila P; Herrera F; Gasch O; Drgona L; Paz Morales H; Brunel AS; García E; Isler B; Kern WV; Morales I; Maestro-de la Calle G; Montero M; Kanj SS; Sipahi OR; Calik S; Márquez-Gómez I; Marin JI; Gomes MZR; Hemmatti P; Araos R; Peghin M; Del Pozo JL; Yáñez L; Tilley R; Manzur A; Novo A; Carratalà J;
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of factor H-related protein 3 in
    González-Alsina A; Martín-Merinero H; Mateu-Borrás M; Verd M; Doménech-Sánchez A; Goldberg JB; Rodríguez de Córdoba S; Albertí S
    Front Immunol; 2024; 15():1449003. PubMed ID: 39295874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunization with outer membrane proteins (OprF and OprI) and flagellin B protects mice from pulmonary infection with mucoid and nonmucoid Pseudomonas aeruginosa.
    Hassan R; El-Naggar W; Abd El-Aziz AM; Shaaban M; Kenawy HI; Ali YM
    J Microbiol Immunol Infect; 2018 Jun; 51(3):312-320. PubMed ID: 28291719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-Life Use of Ceftolozane/Tazobactam for the Treatment of Bloodstream Infection Due to Pseudomonas aeruginosa in Neutropenic Hematologic Patients: a Matched Control Study (ZENITH Study).
    Bergas A; Albasanz-Puig A; Fernández-Cruz A; Machado M; Novo A; van Duin D; Garcia-Vidal C; Hakki M; Ruiz-Camps I; Del Pozo JL; Oltolini C; DeVoe C; Drgona L; Gasch O; Mikulska M; Martín-Dávila P; Peghin M; Vázquez L; Laporte-Amargós J; Durà-Miralles X; Pallarès N; González-Barca E; Álvarez-Uría A; Puerta-Alcalde P; Aguilar-Company J; Carmona-Torre F; Clerici TD; Doernberg SB; Petrikova L; Capilla S; Magnasco L; Fortún J; Castaldo N; Carratalà J; Gudiol C
    Microbiol Spectr; 2022 Jun; 10(3):e0229221. PubMed ID: 35475683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors and mortality of carbapenem-resistant Pseudomonas aeruginosa bloodstream infection in haematology department: A 10-year retrospective study.
    Yuan F; Li M; Wang X; Fu Y
    J Glob Antimicrob Resist; 2024 Jun; 37():150-156. PubMed ID: 38615882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of metallo-β-lactamase production and multidrug resistance on clinical outcomes in patients with Pseudomonas aeruginosa bloodstream infection: a retrospective cohort study.
    Willmann M; Kuebart I; Marschal M; Schröppel K; Vogel W; Flesch I; Markert U; Autenrieth IB; Hölzl F; Peter S
    BMC Infect Dis; 2013 Nov; 13():515. PubMed ID: 24176052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pseudomonas aeruginosa bloodstream infections: risk factors and treatment outcome related to expression of the PER-1 extended-spectrum beta-lactamase.
    Endimiani A; Luzzaro F; Pini B; Amicosante G; Rossolini GM; Toniolo AQ
    BMC Infect Dis; 2006 Mar; 6():52. PubMed ID: 16542460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pseudomonas aeruginosa bacteremia over a 10-year period: multidrug resistance and outcomes in transplant recipients.
    Johnson LE; D'Agata EM; Paterson DL; Clarke L; Qureshi ZA; Potoski BA; Peleg AY
    Transpl Infect Dis; 2009 Jun; 11(3):227-34. PubMed ID: 19302282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bacterial bloodstream infections in level-I trauma intensive care unit in Serbia: incidence, causative agents and outcomes.
    Djuric O; Markovic-Denic L; Jovanovic B; Jovanovic S; Marusic V; Bumbasirevic V
    J Infect Dev Ctries; 2018 Dec; 12(12):1079-1087. PubMed ID: 32027609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of virulence genotype and resistance profile in the mortality of Pseudomonas aeruginosa bloodstream infections.
    Peña C; Cabot G; Gómez-Zorrilla S; Zamorano L; Ocampo-Sosa A; Murillas J; Almirante B; Pomar V; Aguilar M; Granados A; Calbo E; Rodríguez-Baño J; Rodríguez-López F; Tubau F; Martínez-Martínez L; Oliver A;
    Clin Infect Dis; 2015 Feb; 60(4):539-48. PubMed ID: 25378459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pseudomonas aeruginosa bloodstream infections in children: a 9-year retrospective study.
    Pilmis B; Alby-Laurent F; Fasola ML; Seegers V; Guery R; Guet-Revillet H; Postaire M; Toubiana J; Bille E; Lortholary O; Zahar JR
    Eur J Pediatr; 2020 Aug; 179(8):1247-1254. PubMed ID: 32080759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.